January 2020
Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.
New options for advanced prostate cancer
Photo provided by National Institutes of Health
Clinical trials are contributing to the growing knowledge of how targeted therapy, immunotherapy, and oral bioavailable chemotherapy can benefit men with metastatic prostate cancer resistant to standard therapy. At Providence Cancer Institute , three new studies of different approaches are now open to patients:

All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types .
New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.